Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions Vertex Pharmaceuticals is collaborating with Obsidian Therapeutics to develop up to five new gene editing therapies. Obsidian’s technology precisely controls protein expression, a capability the partners plan to apply to several undisclosed serious diseases. Shares0
Cystic fibrosis drugs are the mainstay of the Vertex Pharmaceuticals portfolio now, but the company has been trying to diversity and it has made gene-editing therapies a key part of that strategy. On Thursday, Vertex announced a partnership with Obsidian Therapeutics that gives it access to that biotech’s technology for engineering cell and gene therapies.